Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
Latest newsMore news →
YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2026.20d agoYD Bio, YD Bio US, EG BioMed US, and Numia Health launched a six-month pilot collaboration to evaluate a cross-border clinical workflow for physician-ordered, blood-based cancer testing for patients in British Columbia, Canada.54d agoYD Bio's affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its U.S. laboratory footprint to 46 states for DNA-methylation early cancer detection operations.80d ago